Associated Papers
Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope.
Al-Zoubi RM et al.
Drug Development Research, 2026
Partial truncation of the C-terminal domain of PTCH1 in cancer promotes tumourigenesis by non-canonical activation of a GLI-PI3K loop.
Caballero-Ruiz B et al.
Oncogene, 2026
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
CDCP1-targeting ADC outperforms standard therapies in Ras-mutant pancreatic cancer.
Um YJ et al.
Molecular Therapy. Oncology, 2025
Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer.
Mahat DB et al.
Immunity, 2025
Feasibility of long-read sequencing to identify molecular alterations in an Indonesian cohort of locally advanced to advanced nasopharyngeal cancer.
Handoko et al.
Scientific Reports, 2025
The multifunctional proline-rich domain of p53 tumor suppressor.
Zhang Y et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2025
p53 in colorectal cancer: from a master player to a privileged therapy target.
Yan S et al.
Journal of Translational Medicine, 2025
Arginine Deprivation Induces Quiescence and Confers Vulnerability to Ferroptosis in Colorectal Cancer.
Lin Y et al.
Cancer Research, 2025
Effects of p53 on the Regulation of Carbonic Anhydrase 8 in Human Colorectal Cancer Cells: Interaction Between p53 and Sp1.
Yu JY et al.
Cell Biochemistry and Function, 2025
SOD2 is a regulator of proteasomal degradation promoting an adaptive cellular starvation response.
Ibrahim NK et al.
Cell Reports, 2025
A Truncated Mutation of TP53 Promotes Chemoresistance in Tongue Squamous Cell Carcinoma.
Du X et al.
International Journal of Molecular Sciences, 2025
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.
Bignotti E et al.
International Journal of Cancer, 2025
DNA replication stress underpins the vulnerability to oxidative phosphorylation inhibition in colorectal cancer.
Zhao XH et al.
Cell Death & Disease, 2025
HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer.
Sun Z et al.
Journal for Immunotherapy of Cancer, 2025
Using multiplexed functional data to reduce variant classification inequities in underrepresented populations.
Dawood M et al.
Genome Medicine, 2024
Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics.
Tian X et al.
Oncotarget, 2024
Mutant p53 Exploits Enhancers to Elevate Immunosuppressive Chemokine Expression and Impair Immune Checkpoint Inhibitors in Pancreatic Cancer.
Mahat DB et al.
Biorxiv : the Preprint Server for Biology, 2024
Scalable approaches for generating, validating and incorporating data from high-throughput functional assays to improve clinical variant classification.
Padigepati SR et al.
Human Genetics, 2024
Loss of p53 epigenetically modulates epithelial to mesenchymal transition in colorectal cancer.
Sharma S et al.
Translational Oncology, 2024
LINC01021 Attenuates Expression and Affects Alternative Splicing of a Subset of p53-Regulated Genes.
Kaller M et al.
Cancers, 2024
p53 biology and reactivation for improved therapy in MDS and AML.
Zawacka JE
Biomarker Research, 2024
Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells.
Wang Z et al.
Cancer Discovery, 2024
USP7 regulates growth and maintains the stemness of p53-mutant colorectal cancer cells via stabilizing of mutant p53.
Li X et al.
Frontiers in Oncology, 2024
Single cell multi-omics reveal intra-cell-line heterogeneity across human cancer cell lines.
Zhu Q et al.
Nature Communications, 2023
Comprehensive omics studies of p53 mutants in human cancer.
Malhotra L et al.
Briefings in Functional Genomics, 2023
The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.
Wang Z et al.
Cell Death and Differentiation, 2023
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials.
Nishikawa S et al.
Cancers, 2023
Identification of 3-Phenylquinoline Derivative PQ1 as an Antagonist of p53 Transcriptional Activity.
Wu X et al.
Acs Omega, 2022
Metabolism-Based Molecular Subtyping Endows Effective Ketogenic Therapy in p53-Mutant Colon Cancer.
Tang M et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2022
P63 and P73 Activation in Cancers with p53 Mutation.
Cai BH et al.
Biomedicines, 2022
Butyrate supplementation regulates expression of chromosome segregation 1‑like protein to reverse the genetic distortion caused by p53 mutations in colorectal cancer.
Chang CC et al.
International Journal of Oncology, 2022
Synthetic lethality between TP53 and ENDOD1.
Tang Z et al.
Nature Communications, 2022
Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients.
Hassin O et al.
Nature Communications, 2022
Should mutant TP53 be targeted for cancer therapy?
Wang Z et al.
Cell Death and Differentiation, 2022
Mutant p53: it's not all one and the same.
Kennedy MC et al.
Cell Death and Differentiation, 2022
p53 Signaling on Microenvironment and Its Contribution to Tissue Chemoresistance.
Souza LCME et al.
Membranes, 2022
Mechanistic roles of mutant p53 governing lipid metabolism.
Loughran RM et al.
Advances in Biological Regulation, 2022
Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile.
Brown K et al.
Frontiers in Oncology, 2022
Gene dosage effects of poly(A) track-engineered hypomorphs.
Powell G et al.
Molecular Therapy. Nucleic Acids, 2021
Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms.
Butturini E et al.
Cells, 2021